CAESAREA, Israel, Dec. 23, 2022 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Firm”), developer of minimally-invasive cryoablation know-how, the ProSense® System that destroys tumors by freezing, at present introduced the closing of its beforehand introduced “greatest efforts” public providing of 8,787,880 shares of the Firm’s extraordinary shares (the “Abnormal Shares“) priced at-the-market beneath Nasdaq guidelines at a worth to the general public of $1.65 per share. The gross proceeds of the providing to the Firm have been roughly $14.5 million, earlier than deducting placement agent charges, commissions, and different estimated providing bills.

A.G.P./Alliance International Companions acted as lead placement agent for the providing on a greatest efforts foundation. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as a co-placement agent for the providing.

The Firm intends to make use of the web proceeds from the providing to fund the event of its subsequent technology single Probe and MultiSense techniques, gathering scientific information and including regulatory approvals in new territories and indications, enterprise growth, advertising and marketing and promoting actions in addition to for working capital and basic company functions.

This providing of the Abnormal Shares is being made pursuant to an efficient shelf registration assertion on Kind F-3 (File No. 333-267272) beforehand filed with the U.S. Securities and Alternate Fee (the “SEC”). The providing was made by way of a prospectus complement and accompanying base prospectus. The closing prospectus complement and accompanying prospectus have been filed with the SEC, and can be found on the SEC’s web site positioned at http://www.sec.gov.  Digital copies of the ultimate prospectus complement could also be obtained from A.G.P./Alliance International Companions, 590 Madison Avenue, twenty eighth Flooring, New York, NY 10022, or by phone at (212) 624-2060, or by e mail at [email protected].

This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase nor shall there be any sale of those securities in any state or jurisdiction wherein such supply, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.

About IceCure Medical Ltd.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, a sophisticated liquid-nitrogen-based cryoablation remedy for the therapy of tumors (benign and cancerous) by freezing, with the first focus areas being breast, kidney, bone and lung most cancers. Its minimally invasive know-how is a secure and efficient different to hospital surgical tumor removing that’s simply carried out in a comparatively brief process. The system is marketed and bought worldwide for the indications cleared to-date by the U.S. Meals and Drug Administration and accepted in Europe with the CE Mark.

Ahead Trying Statements

This press launch accommodates forward-looking statements inside the that means of the “secure harbor” provisions of the Personal Securities Litigation Reform Act of 1995, different Federal securities legal guidelines and Israeli securities legal guidelines. Phrases akin to “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and comparable expressions or variations of such phrases are meant to establish forward-looking statements. For instance, IceCure is utilizing ahead trying statements on this press launch when it discusses: meant use of proceeds from its public providing of Abnormal Shares. As a result of such statements cope with future occasions and are based mostly on IceCure’s present expectations, they’re topic to varied dangers and uncertainties and precise outcomes, efficiency, or achievements of IceCure might differ materially from these described in or implied by the statements on this press launch. The forward-looking statements contained or implied on this press launch are topic to different dangers and uncertainties, a lot of that are past the management of the Firm, together with these set forth within the Danger Elements part of the Firm’s Annual Report on Kind 20-F for the yr ended December 31, 2021 filed with the SEC on April 1, 2022, as amended, which is offered on the SEC’s web site, www.sec.gov. The Firm undertakes no obligation to replace these statements for revisions or modifications after the date of this launch, besides as required by legislation.

IR Contact:
Ronen Tsimerman
E-mail: [email protected]

SOURCE IceCure Medical